MartinPLefkowitzMD

Vice-President, Cardiovascular and Renal Therapeutic Area Head, Global Clinical Development, Novartis Pharmaceuticals

Dr. Lefkowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

4157 citations
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J.V. McMurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin Lefkowitz
The New England Journal of Medicine. 2014-09-10
23 citations
Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension
Jon H. Levine, Keith C. Ferdinand, Paul H. Cargo, Harriet Laine, Martin Lefkowitz
American Journal of Hypertension. 1995-05-01
526 citations
Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction
Elisabeth Kraigher-Krainer, Amil M. Shah, Deepak K. Gupta, Angela B. S. Santos, Brian Claggett
Journal of the American College of Cardiology. 2014-02-11

Journal Articles

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients with Heart Failure
Milton Packer, Alvin Chandra, Akshay S. Desai, Martin P Lefkowitz, Martin P. Lefkowitz, Milton Packer, Michael R. Zile, Scot D. Solomon, Michael R Zile, Alvin Chandra,..., JAMA
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
Michael R Zile, Martin P Lefkowitz, Scott D Solomon, Milton Packer, Akshay S Desai, ScienceDirect